(ADPT) Adaptive Biotechnologies - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 2.280m USD | Total Return: 65.6% in 12m

Diagnostics, Research Tools, Therapies, Data Platform
Total Rating 35
Safety 28
Buy Signal -0.70
Biotechnology
Industry Rotation: -3.7
Market Cap: 2.28B
Avg Turnover: 23.9M USD
ATR: 7.28%
Peers RS (IBD): 58.3
Risk 5d forecast
Volatility89.6%
Rel. Tail Risk-16.0%
Reward TTM
Sharpe Ratio0.87
Alpha6.72
Character TTM
Beta1.635
Beta Downside2.400
Drawdowns 3y
Max DD73.41%
CAGR/Max DD0.24
EPS (Earnings per Share) EPS (Earnings per Share) of ADPT over the last years for every Quarter: "2021-03": -0.29, "2021-06": -0.35, "2021-09": -0.4, "2021-12": -0.43, "2022-03": -0.44, "2022-06": -0.37, "2022-09": -0.32, "2022-12": -0.28, "2023-03": -0.4, "2023-06": -0.33, "2023-09": -0.35, "2023-12": -0.3, "2024-03": -0.33, "2024-06": -0.31, "2024-09": -0.22, "2024-12": -0.23, "2025-03": -0.2, "2025-06": -0.17, "2025-09": 0.06, "2025-12": -0.09, "2026-03": 0,
EPS CAGR: 69.73%
EPS Trend: 84.8%
Last SUE: 2.29
Qual. Beats: 5
Revenue Revenue of ADPT over the last years for every Quarter: 2021-03: 38.442, 2021-06: 38.505, 2021-09: 39.467, 2021-12: 37.93, 2022-03: 38.62, 2022-06: 43.66, 2022-09: 47.83, 2022-12: 55.198, 2023-03: 37.647, 2023-06: 48.926, 2023-09: 37.919, 2023-12: 45.784, 2024-03: 41.873, 2024-06: 43.19, 2024-09: 46.435, 2024-12: 47.459, 2025-03: 52.443, 2025-06: 58.879, 2025-09: 93.973, 2025-12: 71.681, 2026-03: null,
Rev. CAGR: 17.93%
Rev. Trend: 66.1%
Last SUE: 1.13
Qual. Beats: 4

Warnings

Interest Coverage Ratio -4.5 is critical

Altman Z'' -11.64 < 1.0 - financial distress zone

Volatile

Tailwinds

No distinct edge detected

Description: ADPT Adaptive Biotechnologies

Adaptive Biotechnologies Corporation (ADPT) is a commercial-stage company focused on immune medicine. It develops an immunosequencing platform that integrates chemistry, computational biology, and machine learning to analyze the adaptive immune system. This approach is common in the biotechnology sector, which increasingly leverages computational methods for biological research.

The company offers the clonoSEQ diagnostic test, which monitors Minimal Residual Disease (MRD) in cancer patients. MRD testing is a growing area in oncology, providing insights into treatment effectiveness and relapse risk. ADPT also provides products and services for life sciences research and drug discovery.

ADPT has a collaboration with Genentech, Inc. for developing T-cell therapies for cancer. Such partnerships are typical in the pharmaceutical industry for sharing development costs and expertise. To explore detailed financial metrics and competitive landscape, consider further research on ValueRay.

Headlines to Watch Out For
  • clonoSEQ diagnostic test adoption drives revenue growth
  • Research product sales contribute to top-line expansion
  • Genentech collaboration milestones impact financial results
  • Clinical trial progress influences investor sentiment
  • Regulatory approvals critical for new product launches
Piotroski VR‑10 (Strict) 2.5
Net Income: -59.5m TTM > 0 and > 6% of Revenue
FCF/TA: -0.10 > 0.02 and ΔFCF/TA 8.79 > 1.0
NWC/Revenue: 75.92% < 20% (prev 103.8%; Δ -27.85% < -1%)
CFO/TA -0.09 > 3% & CFO -46.0m > Net Income -59.5m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 3.34 > 1.5 & < 3
Outstanding Shares: last quarter (153.1m) vs 12m ago 4.10% < -2%
Gross Margin: 74.24% > 18% (prev 0.60%; Δ 7.36k% > 0.5%)
Asset Turnover: 52.65% > 50% (prev 33.18%; Δ 19.47% > 0%)
Interest Coverage Ratio: -4.54 > 6 (EBITDA TTM -37.3m / Interest Expense TTM 11.8m)
Altman Z'' -11.64
A: 0.41 (Total Current Assets 300.2m - Total Current Liabilities 89.9m) / Total Assets 512.7m
B: -2.66 (Retained Earnings -1.36b / Total Assets 512.7m)
C: -0.10 (EBIT TTM -53.5m / Avg Total Assets 526.1m)
D: -4.74 (Book Value of Equity -1.36b / Total Liabilities 287.7m)
Altman-Z'' Score: -11.64 = D
Beneish M -3.08
DSRI: 0.78 (Receivables 50.4m/41.7m, Revenue 277.0m/179.0m)
GMI: 0.80 (GM 74.24% / 59.72%)
AQI: 0.90 (AQ_t 0.27 / AQ_t-1 0.30)
SGI: 1.55 (Revenue 277.0m / 179.0m)
TATA: -0.03 (NI -59.5m - CFO -46.0m) / TA 512.7m)
Beneish M-Score: -3.08 (Cap -4..+1) = AA
What is the price of ADPT shares? As of April 11, 2026, the stock is trading at USD 12.79 with a total of 3,309,954 shares traded.
Over the past week, the price has changed by -9.16%, over one month by -11.91%, over three months by -29.96% and over the past year by +65.57%.
Is ADPT a buy, sell or hold? Adaptive Biotechnologies has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy ADPT.
  • StrongBuy: 3
  • Buy: 4
  • Hold: 1
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the ADPT price?
Analysts Target Price 20.9 63.1%
Adaptive Biotechnologies (ADPT) - Fundamental Data Overview as of 07 April 2026
P/S = 8.2334
P/B = 10.43
Revenue TTM = 277.0m USD
EBIT TTM = -53.5m USD
EBITDA TTM = -37.3m USD
Long Term Debt = 79.1m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 13.6m USD (from shortTermDebt, last quarter)
Debt = 280.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 53.6m USD (recalculated: Debt 280.6m - CCE 227.0m)
Enterprise Value = 2.33b USD (2.28b + Debt 280.6m - CCE 227.0m)
Interest Coverage Ratio = -4.54 (Ebit TTM -53.5m / Interest Expense TTM 11.8m)
EV/FCF = -47.69x (Enterprise Value 2.33b / FCF TTM -48.9m)
FCF Yield = -2.10% (FCF TTM -48.9m / Enterprise Value 2.33b)
FCF Margin = -17.67% (FCF TTM -48.9m / Revenue TTM 277.0m)
Net Margin = -21.48% (Net Income TTM -59.5m / Revenue TTM 277.0m)
Gross Margin = 74.24% ((Revenue TTM 277.0m - Cost of Revenue TTM 71.4m) / Revenue TTM)
Gross Margin QoQ = 74.58% (prev 80.68%)
Tobins Q-Ratio = 4.55 (Enterprise Value 2.33b / Total Assets 512.7m)
Interest Expense / Debt = 1.05% (Interest Expense 2.95m / Debt 280.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -42.3m (EBIT -53.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.34 (Total Current Assets 300.2m / Total Current Liabilities 89.9m)
Debt / Equity = 1.28 (Debt 280.6m / totalStockholderEquity, last quarter 218.8m)
 Debt / EBITDA = -1.44 (negative EBITDA) (Net Debt 53.6m / EBITDA -37.3m)
 Debt / FCF = -1.10 (negative FCF - burning cash) (Net Debt 53.6m / FCF TTM -48.9m)
 Total Stockholder Equity = 198.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -11.31% (Net Income -59.5m / Total Assets 512.7m)
RoE = -30.00% (Net Income TTM -59.5m / Total Stockholder Equity 198.3m)
RoCE = -19.28% (EBIT -53.5m / Capital Employed (Equity 198.3m + L.T.Debt 79.1m))
 RoIC = -21.31% (negative operating profit) (NOPAT -42.3m / Invested Capital 198.3m)
 WACC = 10.54% (E(2.28b)/V(2.56b) * Re(11.73%) + D(280.6m)/V(2.56b) * Rd(1.05%) * (1-Tc(0.21)))
Discount Rate = 11.73% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.80%
 [DCF] Fair Price = unknown (Cash Flow -48.9m)
 EPS Correlation: 84.77 | EPS CAGR: 69.73% | SUE: 2.29 | # QB: 5
Revenue Correlation: 66.11 | Revenue CAGR: 17.93% | SUE: 1.13 | # QB: 4
EPS next Quarter (2026-06-30): EPS=-0.13 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=7
EPS current Year (2026-12-31): EPS=-0.48 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=+7 | Growth EPS=-23.1% | Growth Revenue=+2.0%
EPS next Year (2027-12-31): EPS=-0.27 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=+2 | Growth EPS=+43.8% | Growth Revenue=+22.7%
[Analyst] Revisions Ratio: +0.20 (3 Up / 2 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle